Cold-cough

Commercial

Portfolio-7447-for-WEB

NCE Pipeline

Discovery-7447-for-WEB

Research

Latest Report and Accounts

21995 Vernalis AR15 1.Cover AW - webJune 30, 2015

2014/15 Results Download our latest report...        


Archive

Latest Presentation

ceoSeptember 29, 2015

Our latest presentation is available to view here...


Archive

Share Price

Share price:  56.75p
Change:  0.00 (0.00%)
As at:  09 February 2016 08:06:37
Volume:  0
LSE ID:  VER

Share price details

Latest News

Vernalis Announces Corvus Pharmaceuticals, Inc. as its Worldwide Licensee for their Adenosine Antagonist Program

Adenosine antagonists under development for use in immuno-oncology

Vernalis plc ("Vernalis" or the "Company") today announces Corvus Pharmaceuticals, Inc. ("Corvus") as its licensee for their adenosine antagonist program.

Read more ...

At a glance

More information on Vernalis and it's pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form